Analyst Price Target is $30.00
▲ +893.38% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Sonnet BioTherapeutics in the last 3 months. The average price target is $30.00, with a high forecast of $30.00 and a low forecast of $30.00. The average price target represents a 893.38% upside from the last price of $3.02.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Sonnet BioTherapeutics. This Buy consensus rating has held steady for over two years.
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
Read More
